Sanara MedTech (NASDAQ: SMTI) reported second-quarter earnings per share of $(0.05), missing the analyst consensus estimate of $0.02 by 350 percent. While the company achieved an 8.93 percent year-over-year increase in sales to $28.137 million, it fell short of the $28.950 million revenue consensus by 2.81 percent. The divergence between top-line growth and bottom-line performance highlights ongoing margin pressures, as revenue expansion did not translate into improved profitability metrics for the period.

The earnings miss represents a significant deviation from market expectations, with actual losses per share exceeding estimates by a wide margin. Although the reported loss of $(0.05) per share reflects a 78.26 percent improvement over the $(0.23) per share loss recorded in the same period last year, the failure to meet the positive $0.02 estimate signals continued challenges in cost management or operational efficiency relative to analyst models.

Financial Performance Overview

The company’s financial results for the quarter present a mixed picture of growth and profitability constraints. Revenue growth remained robust compared to the prior year, yet the inability to convert this growth into estimated profit levels suggests structural or temporary headwinds affecting the bottom line.

Year-Over-Year Trends

Comparing the current quarter to the same period last year reveals progress in both revenue generation and loss reduction. Sales rose from $25.831 million to $28.137 million, marking an 8.93 percent increase. Concurrently, the loss per share narrowed significantly from $(0.23) to $(0.05), indicating that while the company has not yet reached profitability, its operational trajectory is improving relative to the previous year.

What the Numbers Show

The primary analytical takeaway is the disconnect between revenue momentum and earnings expectations. While an 8.93 percent sales increase demonstrates demand resilience or successful commercial execution, the 350 percent miss on EPS suggests that costs may have risen disproportionately to revenue, or that one-time items impacted the bottom line more than anticipated. Investors should monitor whether the narrowing loss trend continues alongside revenue growth in subsequent quarters to assess if the company is approaching a sustainable profitability inflection point.

Kahn Swick & Foti, LLC has launched an investigation into the proposed acquisition of Sanara MedTech Inc. (NASDAQ: SMTI) by MiMedx Group, Inc. (NASDAQ: MDXG), joining a growing list of legal firms scrutinizing the transaction’s fairness. The New Orleans-based firm, led by Managing Partner Lewis S. Kahn, is examining whether the mixed cash-and-stock offer adequately values Sanara MedTech or if shareholders are being deprived of superior consideration. This development adds to existing probes by Monteverde & Associates PC, Ademi LLP, and Halper Sadeh LLC, intensifying pressure on the Sanara MedTech Board of Directors to justify the deal structure.

The investigation centers on the merger agreement terms, which value Sanara MedTech at approximately $350 million. Under the proposal, each Sanara shareholder will receive $33.00 in cash and 0.4735 shares of MiMedx common stock for every share held. This totals $35.00 per share, with the equity component valued based on MiMedx’s average closing price of $4.22 over the five trading days ending July 28, 2026. Shareholders face a critical decision on whether to accept this fixed consideration or pursue legal recourse if they believe the process was flawed or the price insufficient.

Transaction Structure

The payment structure aims to balance certainty with equity participation, though critics argue it may limit upside potential for sellers:

Ademi LLP previously alleged that the board failed to secure the best possible price or conduct a conflict-free sales process, highlighting substantial financial benefits for insiders through change-of-control arrangements unavailable to public shareholders. Kahn Swick & Foti is now reviewing these allegations alongside potential breaches of fiduciary duty and violations of federal securities laws.

Fiduciary Duty Allegations

Kahn Swick & Foti is assessing whether the board’s conduct limited shareholder choice by unreasonably restricting competing transactions. The firm asserts that penalty clauses for accepting alternative bids may have discouraged higher offers, potentially depriving shareholders of superior value. This mirrors earlier claims from Halper Sadeh LLC that the process lacked transparency and adequate disclosure of material information. Juan Monteverde of Monteverde & Associates PC has also urged shareholders to evaluate their options, noting his firm operates on a contingent fee basis.

What the Numbers Show

The fixed cash component of $33.00 represents 94% of the total offer value, minimizing exposure to MiMedx’s stock volatility for sellers. However, the reliance on a short-term average for the equity portion introduces valuation risk if MiMedx’s share price fluctuates significantly before closing. The substantial insider benefits, contrasted with these rigid terms, underscore the core tension in the fiduciary duty analysis: whether the board prioritized certainty of closure over maximizing shareholder return. Shareholders can contact Kahn Swick & Foti at (833) 538-3612 or lewis.kahn@ksfcounsel.com to discuss their rights.